Building access to the Regenstrief Institute is restricted at least through September 13, 2020. More on our coronavirus precautions.
See our coronavirus precautions.

A paper authored by Regenstrief research scientist Shelley Johns, PsyD, is one of the most downloaded papers from the well-respected journal, Cancer. The journal reported that “Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: A 3-arm pilot randomized controlled trial” was among the top 10 percent of its downloads over the last year.

The paper published results indicating that acceptance and commitment therapy (ACT) may help treat fear of cancer recurrence in breast cancer survivors. The trial compared ACT, survivorship education, and enhanced usual care. Participants in each group showed reductions in the severity of their fear, but only those who received ACT reported significant improvements at each point of evaluation. The improvements also continued to grow over time.

Fear that cancer may come back or progress is one of the most prevalent, persistent and disruptive problems that survivors face. It is especially common in breast cancer survivors, causing anxiety, depression and overall diminished quality of life.

There are not enough healthcare providers who specialize in fear of recurrence to treat the 17 million cancer survivors in the U.S. Dr. Johns’ study provided evidence that ACT therapy may be an effective tool, offering survivors and therapists more options for treatment.

Cancer has an impact factor of 6.1, which places it in the top 5 percent of the nearly 12,300 journals ranked.

In addition to her role at Regenstrief, Dr. Johns is an assistant professor at Indiana University School of Medicine and a clinical health psychologist in the Eskenazi Health Palliative Care Program. She is a member of the Indiana University Melvin and Bren Simon Cancer Center.

Related Influence

Jul 08, 2020 • Influence
Regenstrief research scientists part of leadership for American Delirium Society Digital Meeting
Dr. Noll Campbell, Dr. Babar Khan, and Dr. Sikandar Khan man "mission control" during the meeting. The COVID-19 pandemic has posed many challenges for conference organizers around the world. Two Regenstrief Institute research scientists successfully adjusted the American Delirium Society (ADS) conference from in-person to virtual and attracted more than 400 registrations from around the…
Continue Reading >
Jul 06, 2020 • Influence
Pandemic spotlights nursing home needs; Regenstrief scientist leading company to address the gaps
Probari, Inc., a company dedicated to improving nursing home care and led by Regenstrief research scientist and Indiana University School of Medicine associate professor Kathleen Unroe, M.D., MHA, was highlighted in Inside Indiana Business. The COVID-19 pandemic has exposed many areas of weakness within the nursing home system, areas that Probari is working to address.…
Continue Reading >